Appeals court upholds patent on Merck's Vytorin
WASHINGTON Feb 7 (Reuters) - A U.S. appeals court on Thursday ruled that the patent on Merck & Co's cholesterol fighter Zetia and a related drug, Vytorin, was valid.
The U.S. Court of Appeals for the Federal Circuit did not discuss the ruling at length and simply affirmed a decision by a lower court in New Jersey.
The U.S. District Court for the District of New Jersey had ruled in April that the patent on Merck's cholesterol fighter Zetia and on Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc until the patent expires.
- Israel pummels Gaza; Kerry steps up diplomatic push |
- Ukraine war crimes trials a step closer after Red Cross assessment
- With sales sputtering, Apple's iPad looks to IBM alliance
- Five held in China food scandal probe, including head of Shanghai Husi Food
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand